283 related articles for article (PubMed ID: 35767258)
1. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis.
Tan DJH; Ng CH; Tay PWL; Syn N; Muthiah MD; Lim WH; Tang ASP; Lim KE; Lim GEH; Tamaki N; Kim BK; Teng MLP; Fung J; Loomba R; Nguyen MH; Huang DQ
JAMA Netw Open; 2022 Jun; 5(6):e2219407. PubMed ID: 35767258
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349
[TBL] [Abstract][Full Text] [Related]
3. The Different Prognoses of Hepatocellular Carcinoma with Previous Tenofovir versus Entecavir Treatment for Chronic Hepatitis B Virus: Analysis Based on 15 Propensity Score-Matched Studies.
Hou J; Qiang Z; Li Y; Zhang Y
Dig Dis; 2023; 41(3):476-488. PubMed ID: 36535244
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH
Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228
[TBL] [Abstract][Full Text] [Related]
5. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
6. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis.
Choi WM; Choi J; Lim YS
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):246-258.e9. PubMed ID: 32407970
[TBL] [Abstract][Full Text] [Related]
7. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.
Yuan J; Peng Y; Hao FB; Wang YQ; Wang CR; Zhong GC
Aging (Albany NY); 2021 Feb; 13(5):7147-7165. PubMed ID: 33658397
[TBL] [Abstract][Full Text] [Related]
8. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
[TBL] [Abstract][Full Text] [Related]
10. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
11. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
Yuan BH; Li RH; Huo RR; Li MJ; Papatheodoridis G; Zhong JH
J Gastroenterol Hepatol; 2022 May; 37(5):782-794. PubMed ID: 35080052
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
Dave S; Park S; Murad MH; Barnard A; Prokop L; Adams LA; Singh S; Loomba R
Hepatology; 2021 Jan; 73(1):68-78. PubMed ID: 32277491
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection.
Li P; Wang Y; Yu J; Yu J; Tao Q; Zhang J; Lau WY; Zhou W; Huang G
JAMA Netw Open; 2023 Oct; 6(10):e2340353. PubMed ID: 37906195
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
Na JE; Sinn DH; Lee JH; Jang HJ; Baek SY; Kim KA; Kang WS; Gwak GY; Paik YH; Kim YJ; Choi MS; Yoon JH; Lee JH; Koh KC; Paik SW
J Viral Hepat; 2021 Oct; 28(10):1392-1399. PubMed ID: 34251707
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
[TBL] [Abstract][Full Text] [Related]
16. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Choi H; Seo GH
J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
Zhang Z; Zhou Y; Yang J; Hu K; Huang Y
BMC Cancer; 2019 May; 19(1):511. PubMed ID: 31142283
[TBL] [Abstract][Full Text] [Related]
18. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
[TBL] [Abstract][Full Text] [Related]
19. Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis.
Cheung KS; Mak LY; Liu SH; Cheng HM; Seto WK; Yuen MF; Lai CL
Clin Transl Gastroenterol; 2020 Oct; 11(10):e00236. PubMed ID: 33031195
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.
Li M; Lv T; Wu S; Wei W; Wu X; Ou X; Ma H; Chow SC; Kong Y; You H; Jia J
Hepatol Int; 2020 Jan; 14(1):105-114. PubMed ID: 31898210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]